Study of Markers of Iron Metabolism and Their Relationship With Phosphocalcic and Hepatic Metabolism and Inflammation in Hemodialysis Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRamsay Générale de Santé

About this trial

From a scientific point of view and for publication purposes, it therefore seems important to study the metabolism of iron and in particular to define its conditions of absorption, metabolism, elimination and storage in the body at course of advanced renal failure.

The study will follow the evolution of hormones regulating iron metabolism and put into perspective their links with phosphocalcic and hepatic metabolisms as well as inflammation in hemodialysis patients.

The main objective of this program is to study the evolution of hepcidin and erythroferrone levels in hemodialysis patients. These two biomarkers regulating iron metabolism are not performed routinely in dialysis centers and are not listed in the nomenclature.

Eligibility criteria

Qualifiers

Adult dialysis patient

Patient able to understand the information necessary for the study and having signed his written consent to participate

Affiliated patient or beneficiary of a social security scheme.

Disqualifiers

Medically unstable or frail patient

Patient with hemoglobin less than 7g/dl

Patient with HIV+ or AIDS, patient with replicating hepatitis B or C

Patient participating in another clinical study requiring an additional blood sample

Trial design

Treatments tested in this trial

  • Blood test

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators

Ramsay Générale de Santé

Lead sponsor

European Clinical Trial Experts Network

Collaborator